Scarica l'app Stockscreener
55.08
2.87%
-1.63
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update - Finviz
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts - ts2.tech
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors - ts2.tech
Cathie Wood’s ARK boosts CRISPR stock with significant buy - Investing.com
CRISPR Therapeutics (CRSP) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
CRISPR Therapeutics (CRSP): Reassessing Valuation After Positive Zugo‑cel Data and New Eli Lilly Collaboration - simplywall.st
CRISPR Therapeutics AG Stock Analysis and ForecastVolume Profile Analysis & Low Entry Investment Portfolio - earlytimes.in
Is CRISPR Therapeutics stock yesterday's news? - MSN
Is CRISPR Therapeutics Stock Yesterday's News? - Finviz
Is CRISPR Therapeutics Stock Yesterday's News? - The Motley Fool
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
CRISPR Therapeutics AG (CRSP) stock falls amid market uptick: What investors need to know - MSN
Citizens Reiterates CRISPR Therapeutics (CRSP) Market Outperform Recommendation - Nasdaq
Crispr Therapeutics Insider Sold Shares Worth $559,549, According to a Recent SEC Filing - marketscreener.com
CRISPR Therapeutics (CRSP) CFO reports 10,000-share sale in Form 4 - Stock Titan
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - Finviz
CRSP Maintains Market Outperform Rating: Latest Analyst Insights | CRSP Stock News - GuruFocus
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies - Finviz
Early but Compelling CTX112 Data Underpin Buy Rating and $80 Target for CRISPR Therapeutics - TipRanks
Citizens Jmp Reaffirms Market Outperform Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Receives Buy Rating from Needham & Company LLC - MarketBeat
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies - Sahm
CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer - Sahm
CRISPR Therapeutics: Early Autoimmune Promise, Best-in-Class Oncology Data, and Eli Lilly Partnership Support Buy Rating - TipRanks
Crispr Therapeutics provides updates on zugo-cel - TipRanks
CRISPR Says Zugo-cel Well-Tolerated in Phase 1 Autoimmune Rheumatic Diseases Trial - marketscreener.com
CRSP Advances Zugo-cel CAR T Therapy with Promising Clinical Res - GuruFocus
CRISPR Therapeutics Reports Promising Early Results for Zugo-cel in Autoimmune Diseases and Oncology Trials - Quiver Quantitative
CRISPR Therapeutics Provides Broad Update on Zugocaptagene - GlobeNewswire
Entry Recap: Is CRISPR Therapeutics AG stock positioned for long term growth2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
How Investors May Respond To CRISPR Therapeutics (CRSP) Earnings Amid Slow Casgevy Uptake Concerns - simplywall.st
What dividend safety rating applies to CRISPR Therapeutics AG (1CG) stockProfit Target & Technical Confirmation Trade Alerts - Улправда
Investor Mood: Is CRISPR Therapeutics AG stock a smart buy before Fed meetingInsider Selling & High Accuracy Investment Signals - Улправда
Trading the Move, Not the Narrative: (CRSP) Edition - news.stocktradersdaily.com
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
Is CRISPR Therapeutics AG stock positioned for long term growthJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - Улправда
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? - Yahoo Finance
Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? - Finviz
CRISPR Therapeutics (CRSP): Reassessing Valuation After a 13% Pullback and Strong Year‑to‑Date Gains - simplywall.st
CRISPR Therapeutics (CRSP): Revisiting Valuation After Recent Share Price Pullback - Yahoo Finance
Is the Market Bullish or Bearish on CRISPR Therapeutics AG? - Benzinga
What analysts say about CRISPR Therapeutics AG stockIndustrial Stocks Review & Minimal Capital Trading Tips - earlytimes.in
Why CRISPR Therapeutics AG (1CG) stock could be next leaderJuly 2025 Spike Watch & Fast Exit and Entry Strategy Plans - Улправда
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
2 Monster Stocks in the Making to Buy and Hold - Finviz
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance - MSN
Marex Group plc Invests $948,000 in CRISPR Therapeutics AG $CRSP - MarketBeat
Biomedical Crispr Gene Editing Market Set for Dynamic - openPR.com
Nikko Asset Management Americas Inc. Sells 125,618 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Why is CRISPR Therapeutics (CRSP) up 3.3% since last earnings report? - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
2 Healthcare Stocks to Buy Ahead of the New Year - Finviz
New York State Common Retirement Fund Increases Position in CRISPR Therapeutics AG $CRSP - MarketBeat
0.08%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):